Antibody-based strategies to prevent and treat influenza

Frontiers in Immunology

Volumn 6, Issue JUN, 2015, Pages

  Shriver, Zachary ^a   Trevejo, Jose M ^a   Sasisekharan, Ram ^b,c  

^a VISTERRA INC   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c SINGAPORE MIT ALLIANCE FOR RESEARCH AND TECHNOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

BINDING AFFINITY; CRITICALLY ILL PATIENT; GENE MUTATION; GENE SEQUENCE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLUENZA; META ANALYSIS (TOPIC); MORTALITY; PASSIVE IMMUNIZATION; POST EXPOSURE PROPHYLAXIS; SHORT SURVEY; VACCINATION;

EID: 84935055481     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00315     Document Type: Short Survey

References (44)

1. Treanor, J.J., et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA: the journal of the American Medical Association 283, 1016-1024 (2000).
2. Schanzer, D.L., Langley, J.M. & Tam, T.W. Co-morbidities associated with influenza-attributed mortality, 1994-2000, Canada. Vaccine 26, 4697-4703 (2008).
3. Control, C.f.D. Estimates of Deaths Associated with Seasonal Influenza US, 1976-2007; MMWR., Vol. 59 1057-1062 (2012).
4. Dawood, F.S., et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. The Lancet infectious diseases 12, 687-695 (2012).
5. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza, A.V., et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358, 261-273 (2008).
6. Hayden, F.G. & de Jong, M.D. Emerging influenza antiviral resistance threats. J Infect Dis 203, 6-10 (2011).
7. Saylor, C., Dadachova, E. & Casadevall, A. Monoclonal antibody-based therapies for microbial diseases. Vaccine 27 Suppl 6, G38-46 (2009).
8. Beigel, J.H., et al. Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus. Antimicrob Agents Chemother 54, 2431-2436 (2010).
9. Chung, R., Gordon, F., Curry, M. & Ambrosino, D. Human Monoclonal Antibody MBL-HCV1 Suppresses Return of HCV Following Liver Transplantation: A Randomized, Controlled Study. (Submitted).
10. Leav, B., Kulkarni, P., Gogtay, N. & Ambrosino, D. A Human Monoclonal to Rabies Virus Provides Protective Neutralizing Activity: Results of a Phase I Study. in ICAAC (Boston, 2010).
11. Chung, R.T., et al. Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 13, 1047-1054 (2013).
12. Malley, R., et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 178, 1555-1561 (1998).
13. Lambert, L.C. & Fauci, A.S. Influenza vaccines for the future. The New England journal of medicine 363, 2036-2044 (2010).
14. Winokur, P.L. & Stapleton, J.T. Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis 14, 580-586 (1992).
15. Luke, T.C., Kilbane, E.M., Jackson, J.L. & Hoffman, S.L. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Annals of internal medicine 145, 599-609 (2006).
16. Hung, I.F., et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 52, 447-456 (2011).
17. DeKosky, B.J., et al. In-depth determination and analysis of the human paired heavy- and lightchain antibody repertoire. Nature medicine 21, 86-91 (2015).
18. Laserson, U., et al. High-resolution antibody dynamics of vaccine-induced immune responses. Proceedings of the National Academy of Sciences of the United States of America 111, 4928-4933 (2014).
19. Jackson, K.J., et al. Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements. Cell host & microbe 16, 105-114 (2014).
20. Mallajosyula, V.V., et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proceedings of the National Academy of Sciences of the United States of America 111, E2514-2523 (2014).
21. Krammer, F., Palese, P. & Steel, J. Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Current topics in microbiology and immunology 386, 301-321 (2015).
22. Wang, S., et al. Manipulating the Selection Forces during Affinity Maturation to Generate Cross- Reactive HIV Antibodies. Cell 160, 785-797 (2015).
23. Hashem, A.M., et al. Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus. Biochem Biophys Res Commun 403, 247- 251 (2010).
24. Ekiert, D.C., et al. A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses. Science (2011).
25. Walker, L.M., et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470 (2011).
26. Lingwood, D., et al. Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 489, 566-570 (2012).
27. Pappas, L., et al. Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature 516, 418-422 (2014).
28. Grandea, A.G., III, et al. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A 107, 12658-12663 (2010).
29. Corti, D., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850-856 (2011).
30. Ekiert, D.C., et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333, 843-850 (2011).
31. Ekiert, D.C., et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246-251 (2009).
32. Li, N., et al. Influenza viral neuraminidase primes bacterial coinfection through TGF-betamediated expression of host cell receptors. Proceedings of the National Academy of Sciences of the United States of America 112, 238-243 (2015).
33. Throsby, M., et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3, e3942 (2008).
34. Sui, J., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16, 265-273 (2009).
35. Wu, N.C., et al. High-throughput profiling of influenza A virus hemagglutinin gene at singlenucleotide resolution. Scientific reports 4, 4942 (2014).
36. Soundararajan, V., et al. Networks link antigenic and receptor-binding sites of influenza hemagglutinin: mechanistic insight into fitter strain propagation. Scientific reports 1, 200 (2011).
37. Nakamura, G., et al. An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell host & microbe 14, 93-103 (2013).
38. He, W., et al. Broadly-Neutralizing Anti-Influenza Virus Antibodies: Enhancement of Neutralizing Potency in Polyclonal Mixtures and IgA Backbones. Journal of virology (2015).
39. DiLillo, D.J., Tan, G.S., Palese, P. & Ravetch, J.V. Broadly neutralizing hemagglutinin stalkspecific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nature medicine 20, 143-151 (2014).
40. Tharakaraman, K., Subramanian, V., Cain, D., Sasisekharan, V. & Sasisekharan, R. Broadly neutralizing influenza hemagglutinin stem-specific antibody CR8020 targets residues that are prone to escape due to host selection pressure. Cell host & microbe 15, 644-651 (2014).
41. Spiess, C., Zhai, Q. & Carter, P.J. Alternative molecular formats and therapeutic applications for bispecific antibodies. Molecular immunology (2015).
42. DiGiandomenico, A., et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Science translational medicine 6, 262ra155 (2014).
43. Tan, W., et al. A bispecific antibody against two different epitopes on hepatitis B surface antigen has potent hepatitis B virus neutralizing activity. mAbs 5, 946-955 (2013).
44. Galimidi, R.P., et al. Intra-Spike Crosslinking Overcomes Antibody Evasion by HIV-1. Cell 160, 433-446 (2015).